Search Results

KSQ Therapeutics, Inc., a clinical-stage biotechnology company developing treatments for solid tumors, announced the first patient dosed in the Phase 1/2 clinical study of KSQ-001EX, a novel edited TIL therapy.

KSQ Therapeutics, Inc. in collaboration with The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), today announced the Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for a Phase 1/2 clinical study of KSQ-001EX.

KSQ Therapeutics, Inc. announced today it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of KSQ-4279.

KSQ Therapeutics, Inc. and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced a strategic collaboration to expedite the development of KSQ’s two lead engineered tumor-infiltrating lymphocyte programs, KSQ-001EX and KSQ-004EX, both of which are advancing toward clinical studies for the treatment of solid tumors.

KSQ Therapeutics Announces Ono Pharmaceutical Co., Ltd. is Acquiring Multiple Research-Stage Oncology Programs Identified with KSQ’s CRISPRomics ® Platform Technology.

KSQ Therapeutics today announced the initiation of dosing in the combination therapy portion of Study KSQ-4279-1101, a Phase 1 clinical study of KSQ-4279 in patients with advanced solid tumors.